Bristol-Myers Squibb Announces European Patent Office Decision On Sprycel

Bristol-Myers Squibb Company (NYSE: BMY) announced today that the European Patent Office (EPO) upheld a decision with regard to European Patent No. 1169038 (the '038 patent), the Composition of Matter patent covering dasatinib, the active ingredient in Sprycel. The EPO upheld a decision that found the patent to be invalid. This decision does not impact our patents outside of the EU or other Sprycel-related patents. BMS has a long-standing heritage in oncology. Sprycel will continue to be a significant asset in our broad oncology portfolio and an important treatment option for patients living with chronic myeloid leukemia (CML). For more in depth information on Bristol-Myers Squibb announcing European Patent Office decision on Sprycel click on the picture below to read the entire press release.